These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

430 related articles for article (PubMed ID: 26123705)

  • 1. Clinical Pharmacokinetics and Pharmacodynamics of Monoclonal Antibodies Approved to Treat Rheumatoid Arthritis.
    Ternant D; Bejan-Angoulvant T; Passot C; Mulleman D; Paintaud G
    Clin Pharmacokinet; 2015 Nov; 54(11):1107-23. PubMed ID: 26123705
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Golimumab pharmacokinetics after repeated subcutaneous and intravenous administrations in patients with rheumatoid arthritis and the effect of concomitant methotrexate: an open-label, randomized study.
    Zhuang Y; Xu Z; Frederick B; de Vries DE; Ford JA; Keen M; Doyle MK; Petty KJ; Davis HM; Zhou H
    Clin Ther; 2012 Jan; 34(1):77-90. PubMed ID: 22169051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and safety of golimumab, a fully human anti-TNF-alpha monoclonal antibody, in subjects with rheumatoid arthritis.
    Zhou H; Jang H; Fleischmann RM; Bouman-Thio E; Xu Z; Marini JC; Pendley C; Jiao Q; Shankar G; Marciniak SJ; Cohen SB; Rahman MU; Baker D; Mascelli MA; Davis HM; Everitt DE
    J Clin Pharmacol; 2007 Mar; 47(3):383-96. PubMed ID: 17322150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegylation of biological molecules and potential benefits: pharmacological properties of certolizumab pegol.
    Pasut G
    BioDrugs; 2014 Apr; 28 Suppl 1():S15-23. PubMed ID: 24687235
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis.
    Wisniacki N; Amaravadi L; Galluppi GR; Zheng TS; Zhang R; Kong J; Burkly LC
    Clin Ther; 2013 Aug; 35(8):1137-49. PubMed ID: 23928094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A guide to rational dosing of monoclonal antibodies.
    Bai S; Jorga K; Xin Y; Jin D; Zheng Y; Damico-Beyer LA; Gupta M; Tang M; Allison DE; Lu D; Zhang Y; Joshi A; Dresser MJ
    Clin Pharmacokinet; 2012 Feb; 51(2):119-35. PubMed ID: 22257150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy.
    Kavanaugh A; St Clair EW; McCune WJ; Braakman T; Lipsky P
    J Rheumatol; 2000 Apr; 27(4):841-50. PubMed ID: 10782805
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy.
    Mori S
    Mod Rheumatol; 2007; 17(2):83-91. PubMed ID: 17437161
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmaceutical aspects of anti-inflammatory TNF-blocking drugs.
    Jinesh S
    Inflammopharmacology; 2015 Jun; 23(2-3):71-7. PubMed ID: 25687751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The underlying inflammatory chronic disease influences infliximab pharmacokinetics.
    Passot C; Mulleman D; Bejan-Angoulvant T; Aubourg A; Willot S; Lecomte T; Picon L; Goupille P; Paintaud G; Ternant D
    MAbs; 2016 Oct; 8(7):1407-1416. PubMed ID: 27589009
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The relationship of serum infliximab concentrations to clinical improvement in rheumatoid arthritis: results from ATTRACT, a multicenter, randomized, double-blind, placebo-controlled trial.
    St Clair EW; Wagner CL; Fasanmade AA; Wang B; Schaible T; Kavanaugh A; Keystone EC
    Arthritis Rheum; 2002 Jun; 46(6):1451-9. PubMed ID: 12115174
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Maintenance of Clinical and Radiographic Benefit With Intravenous Golimumab Therapy in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy: Week-112 Efficacy and Safety Results of the Open-Label Long-Term Extension of a Phase III, Double-Blind, Randomized, Placebo-Controlled Trial.
    Bingham CO; Mendelsohn AM; Kim L; Xu Z; Leu J; Han C; Lo KH; Westhovens R; Weinblatt ME;
    Arthritis Care Res (Hoboken); 2015 Dec; 67(12):1627-36. PubMed ID: 25623393
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis).
    Furst DE; Schiff MH; Fleischmann RM; Strand V; Birbara CA; Compagnone D; Fischkoff SA; Chartash EK
    J Rheumatol; 2003 Dec; 30(12):2563-71. PubMed ID: 14719195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics, pharmacodynamics and physiologically-based pharmacokinetic modelling of monoclonal antibodies.
    Dostalek M; Gardner I; Gurbaxani BM; Rose RH; Chetty M
    Clin Pharmacokinet; 2013 Feb; 52(2):83-124. PubMed ID: 23299465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
    Glassman PM; Balthasar JP
    J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab: Review of the efficacy and tolerability of a recently approved tumor necrosis factor-α inhibitor.
    Boyce EG; Halilovic J; Stan-Ugbene O
    Clin Ther; 2010 Sep; 32(10):1681-703. PubMed ID: 21194591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Subcutaneously administered ofatumumab in rheumatoid arthritis: a phase I/II study of safety, tolerability, pharmacokinetics, and pharmacodynamics.
    Kurrasch R; Brown JC; Chu M; Craigen J; Overend P; Patel B; Wolfe S; Chang DJ
    J Rheumatol; 2013 Jul; 40(7):1089-96. PubMed ID: 23729801
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunogenicity of infliximab and adalimumab: what is its role in hypersensitivity and modulation of therapeutic efficacy and safety?
    Murdaca G; Spanò F; Contatore M; Guastalla A; Penza E; Magnani O; Puppo F
    Expert Opin Drug Saf; 2016 Jan; 15(1):43-52. PubMed ID: 26559805
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Population pharmacokinetic analysis of tocilizumab in patients with rheumatoid arthritis.
    Frey N; Grange S; Woodworth T
    J Clin Pharmacol; 2010 Jul; 50(7):754-66. PubMed ID: 20097931
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.